Evidence map›Paper›PMID 39997461›Full record

ArticleInfectious disease reports2025

Mpox Cases in Serbia, 2022.

Petar Đurić, Verica Jovanović, Mitra B Drakulović, Dragana Plavša, Jovan Malinić, Aleksandar Medarević, Jelena Protić, Nana Mebonia

Abstract read
In one paragraph

Article in Infectious disease reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Petar ĐurićNational Public Health Institute "Dr. Milan Jovanović Batut", 11000 Belgrade, Serbia.ORCID 0000-0002-0881-5170
Verica JovanovićNational Public Health Institute "Dr. Milan Jovanović Batut", 11000 Belgrade, Serbia.
Mitra B DrakulovićNational Public Health Institute "Dr. Milan Jovanović Batut", 11000 Belgrade, Serbia.
Dragana PlavšaNational Public Health Institute "Dr. Milan Jovanović Batut", 11000 Belgrade, Serbia.
Jovan MalinićClinic for Infectious and Tropical Diseases, University Clinical Center of Serbia, 11000 Belgrade, Serbia.
Aleksandar MedarevićNational Public Health Institute "Dr. Milan Jovanović Batut", 11000 Belgrade, Serbia.ORCID 0000-0002-7483-3625
Jelena ProtićThe Institute of Virology, Vaccines, and Sera "Torlak", 11000 Belgrade, Serbia.ORCID 0000-0002-8024-1204
Nana MeboniaMediterranean and Black Sea Program in Intervention Epidemiology Training (MediPIET), European Center for Disease Prevention and Control (ECDC), 16973 Stockholm, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOn 23 July 2022, the World Health Organization (WHO) declared the mpox multi-country outbreak as a Public Health Emergency of International Concern. This study aimed to identify the epidemiological and clinical characteristics of confirmed mpox cases reported in Serbia in 2022.

methodsThe mpox WHO case definition was used. Incidence rates (IRs) and incidence rate ratios (IRRs) by age groups and nomenclature of territorial units for statistics level 3 (NUTS-3) with 95% confidence intervals (CIs) were calculated.

resultsBetween June and October 2022, 43 laboratory-confirmed cases were reported. All were unvaccinated males, with the mean age of 34 (±7.4) years. Out of the total, 72.1% cases were men who have sex with men (MSM), who reported sexual intercourse either with multiple or unknown partners (

conclusionsIn Serbia, mpox mainly affected MSM aged 30-39 and living in urban areas. Health promotion and vaccine implementation should be prioritized in populations with a higher risk.

Indexed as

men who have sex with menmpoxoutbreakSerbiasexually transmitted infections

Identifiers

PMID39997461
PMCPMC11855485

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.